Browsing Category
Medicine
Pfizer: Pfizer Granted FDA Breakthrough Therapy Designation for Respiratory Syncytial Virus Vaccine…
Pfizer Inc. (NYSE:PFE) today announced that its respiratory syncytial virus (RSV) vaccine candidate, PF-06928316 or RSVpreF, received Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA) for the prevention of!-->…
Pfizer: Pfizer to Supply UNICEF up to 4 Million Treatment Courses of Novel COVID-19 Oral Treatment…
Pfizer Inc. (NYSE: PFE) announced today an agreement with UNICEF to supply up to 4 million treatment courses of its COVID-19 oral treatment, PAXLOVID™ (nirmatrelvir tablets and ritonavir tablets), to 95 low- and middle-income countries,!-->…
Pfizer: Pfizer and BioNTech Submit for U.S. Emergency Use Authorization of an Additional Booster…
Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced the companies have submitted an application to the U.S. Food and Drug Administration (FDA) for Emergency Use Authorization (EUA) of an additional booster dose adults!-->…
LILA Games, A Mobile F2P Game Studio, Raises $10M Series A, To Launch New Game & Grow Team
BANGALORE — LILA Games, a F2P mobile game studio, announced a $10 million Series A financing round. The round was led by Rainfall and included participation from BITKRAFT Ventures, Galaxy Interactive, Sequoia Capital, and KRAFTON, Inc. In…
Pfizer: Pfizer Initiates Phase 2/3 Study of Novel COVID-19 Oral Treatment in Pediatric Participants
Pfizer Inc. (NYSE: PFE) announced today that it has initiated a Phase 2/3 study, EPIC-PEDS (Evaluation of Protease Inhibition for COVID-19 in Pediatric Patients), to evaluate the safety, pharmacokinetics, and efficacy of Pfizer’s!-->…
Pfizer: Pfizer Granted FDA Breakthrough Therapy Designation for Respiratory Syncytial Virus (RSV)…
Pfizer Inc. (NYSE:PFE) today announced that its respiratory syncytial virus (RSV) vaccine candidate, PF-06928316 or RSVpreF, received Breakthrough Therapy Designation from the US Food and Drug Administration (FDA) for prevention of!-->…
Pfizer: Phase 3 CLOVER Trial for Pfizer’s Investigational Clostridioides Difficile Vaccine Indicates…
Pfizer Inc. (NYSE:PFE) today announced results from the CLOVER trial (CLOstridium difficile Vaccine Efficacy TRial), a pivotal Phase 3 study evaluating its Clostridioides difficile (C. difficile)vaccine candidate (PF-06425090) in the!-->…
Pfizer: European Medicines Agency Approves Pfizer’s 20-Valent Pneumococcal Conjugate Vaccine Against…
Pfizer Inc. (NYSE:PFE) today announced that the European Medicines Agency (EMA) has approved the company’s 20-valent pneumococcal conjugate vaccine (PCV20), which will be marketed in the European Union (EU) under the brand name APEXXNAR.!-->…
Pfizer: Pfizer and OPKO’s Once-Weekly NGENLA™ (somatrogon) Injection Receives Marketing…
Pfizer Inc. (NYSE: PFE) and OPKO Health, Inc. (NASDAQ: OPK) announced today that the European Commission has granted marketing authorization for the next-generation long-acting recombinant human growth hormone NGENLA™ (somatrogon), a!-->…
Liang Named Medical Director of the Johns Hopkins Center for Transgender Health
Johns Hopkins Medicine has announced that plastic and reconstructive surgeon Fan Liang, M.D., will become the next medical director of the Johns Hopkins Center for Transgender Health (CTH), one of the premier institutions of its kind in the…